Dilaudid (hydromorphone) is significantly stronger than Demerol (meperidine) on a milligram-for-milligram basis. When taken by mouth, 1 mg of Dilaudid provides roughly the same pain relief as 50 mg of Demerol. That makes Dilaudid about 50 times more potent per milligram, though potency alone doesn’t tell the whole story about which drug works better or safer in a given situation.
How Their Potency Compares
The standard way to compare opioid strength is by converting each drug to its oral morphine equivalent. Using the conversion factors from UCSF’s pain management program, 1 mg of oral hydromorphone equals about 5 mg of oral morphine, while 1 mg of oral meperidine equals only 0.1 mg of oral morphine. That means hydromorphone is 50 times more potent by weight when taken orally.
Through an IV, the gap narrows slightly but remains dramatic. One milligram of IV hydromorphone equals 18 mg of oral morphine, while 1 mg of IV meperidine equals 0.3 mg. Meperidine has been described in pharmacology literature as roughly one-tenth as effective as morphine, making it one of the weakest opioids in clinical use. Hydromorphone, by contrast, sits near the top of the potency scale alongside fentanyl.
Higher potency doesn’t mean a bigger “effect” in practice. It simply means you need a much smaller dose of Dilaudid to achieve the same level of pain relief. A patient receiving either drug at the correct equivalent dose would, in theory, experience similar pain control.
How They Work Differently in the Body
Both drugs activate the same primary pain receptor in the brain and spinal cord (the mu-opioid receptor), but they differ in important ways beyond raw strength. Hydromorphone is a pure mu-receptor agonist that also has minor activity at delta opioid receptors. It reaches peak pain relief about 30 to 60 minutes after an oral dose and lasts roughly 3 to 4 hours.
Meperidine has a more complicated profile. Beyond its weak opioid activity, it has properties similar to local anesthetics and anticholinergic drugs (the kind that dry out secretions and can cause confusion). These extra effects are part of the reason meperidine behaves differently from other opioids in certain situations, particularly when it comes to side effects and toxicity.
Why Demerol Has Fallen Out of Favor
Demerol was once one of the most commonly prescribed opioids in hospitals, but its use has dropped sharply over the past two decades. The main reason is a toxic byproduct. When your body breaks down meperidine, it produces a metabolite called normeperidine. This substance builds up with repeated doses and can cause a range of neurological problems: anxiety, tremors, muscle twitching, delirium, and in serious cases, seizures. Critically, the overdose-reversal drug naloxone does not reverse these neurological effects.
The risk climbs quickly in certain groups. In people with kidney problems, normeperidine’s half-life stretches to about 34 hours, meaning it accumulates much faster than the body can clear it. Liver disease creates a similar problem: even though the liver converts less meperidine to normeperidine, the metabolite that does form gets eliminated more slowly. The FDA’s prescribing label explicitly states that meperidine should not be used for chronic pain and should only treat short-term, acute pain episodes.
The VA and Department of Defense guidelines cap meperidine use at a maximum of 600 mg in a 24-hour period and recommend stopping it entirely after 24 hours. The American Geriatrics Society’s Beers Criteria, a widely used list of drugs to avoid in older adults, flags meperidine specifically for its risk of neurotoxicity and delirium.
Why Demerol Is Still Used at All
Given its toxicity concerns, you might wonder why meperidine hasn’t disappeared entirely. It retains a few narrow uses. Its unique pharmacological properties make it effective at treating post-anesthesia shivering, a common problem after surgery where the body shakes uncontrollably during recovery. For this specific purpose, a single low dose can work well without the risks that come with repeated dosing. Outside of situations like this, most hospitals have either restricted or eliminated meperidine from their formularies.
How Dilaudid Compares for Safety
Hydromorphone carries the standard risks of any potent opioid: respiratory depression, sedation, constipation, nausea, and the potential for dependence. But it does not produce a neurotoxic metabolite the way meperidine does, which gives it a meaningful safety advantage for anyone who needs more than a single dose.
For people with kidney disease, hydromorphone requires dose adjustments and careful monitoring, but it can still be used safely. Meperidine, by contrast, is considered contraindicated in renal impairment because of the normeperidine accumulation risk. This distinction matters in real-world prescribing: a patient with reduced kidney function who needs strong pain relief is far more likely to be offered hydromorphone (or another alternative) than meperidine.
Potency vs. Effectiveness
When people ask whether one opioid is “stronger” than another, they usually want to know which one controls pain better. The answer is that potency and effectiveness are separate concepts. Hydromorphone is far more potent, meaning you need less of it. But when each drug is given at the right equivalent dose, both can control moderate to severe pain.
The practical difference comes down to side effects, safety margins, and how long each drug can be used. On all three counts, hydromorphone has advantages. Meperidine’s toxicity profile, short recommended duration of use (24 hours maximum), and restrictions in older adults and people with organ impairment make it a poor choice for most pain management needs. That’s why Dilaudid and similar opioids have largely replaced Demerol in modern practice, not because they produce more pain relief per dose, but because they can do so more safely and for longer periods when needed.